Phase I-II Clinical Trial for the Evaluation of Brentuximab Vedotin Plus Etoposide, Solumoderin (Methylprednisolone), High Dose ARA-C (Cytarabine) and Cisplatin in the Transplant and Post-transplant Management for Relapsed or Refractory Classical Hodgkin Lymphoma Patients
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 27 Sep 2018
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cisplatin; Cytarabine; Etoposide; Methylprednisolone
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms GELTAMO
- 20 Sep 2018 Planned End Date changed from 18 Aug 2018 to 1 Jan 2019.
- 20 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Nov 2018.
- 31 Aug 2018 Biomarkers information updated